首页> 外文期刊>Research in Veterinary Science >A genetically engineered derivative of Salmonella Enteritidis as a novel live vaccine candidate for salmonellosis in chickens.
【24h】

A genetically engineered derivative of Salmonella Enteritidis as a novel live vaccine candidate for salmonellosis in chickens.

机译:肠炎沙门氏菌的基因工程衍生物,可作为鸡沙门氏菌病的新型活疫苗候选物。

获取原文
获取原文并翻译 | 示例
           

摘要

To construct a novel live Salmonella Enteritidis (SE) vaccine candidate, SE was genetically engineered using the allelic exchange method to delete two virulence genes, lon and cpxR. The lon gene deletion is essential to impair Salmonella replication and avoid overwhelming systemic disease in the host. The cpxR gene deletion is needed to enhance the ability of bacteria to adhere and invade the host cell. Scanning electron microscopy revealed that the derivatives JOL917 ([Greek capital Delta]lon), JOL918 ([Greek capital Delta]cpxR), and JOL919 ([Greek capital Delta]lon/[Greek capital Delta]cpxR) had increased surface fimbrial filamentous structures. Significant elevations of extracellular polysaccharide and FimA expression were observed for the derivatives compared to the parental wild type JOL860, while biochemical properties of the derivatives were not altered. In the safety examination by inoculation of the derivatives in chickens, gross lesion scores of the liver, spleen, kidney, small intestine and caecal tonsils were moderate in the JOL917 and JOL918 groups, and significantly lower in the JOL919 group than those of the JOL860. Bacterial counts from the spleen and caeca of the JOL917 and JOL918 groups were moderate, and significantly reduced in the JOL919 group compared to the JOL860 group. In addition, only the JOL919 group showed significantly lower bacterial counts in the faecal samples than those of the JOL860 group. Significant elevations of IgG and secretory IgA levels observed in the derivative groups, while the JOL919 and JOL860 groups showed a potent lymphocyte proliferation response as compared to those of the control group. In the protection efficacy examination, JOL919 immunized group showed significantly lower depression, lower gross lesion in the liver and spleen, and lower number of the SE positive internal organs than those of the control group against a virulent wild type SE challenge
机译:为了构建新型的活肠炎沙门氏菌(SE)候选疫苗,使用等位基因交换方法对SE进行了基因工程改造,以删除两个毒力基因lon和cpxR。 lon基因缺失对于损害沙门氏菌复制和避免宿主体内压倒性全身疾病至关重要。需要cpxR基因缺失来增强细菌粘附和侵袭宿主细胞的能力。扫描电子显微镜显示,衍生物JOL917(希腊资本),JOL918(希腊资本/ cpxR)和JOL919(希腊资本/希腊资本)具有增加的表面纤维丝状结构。 。与亲本野生型JOL860相比,观察到衍生物的胞外多糖和FimA表达显着升高,而衍生物的生化特性没有改变。在通过在鸡中接种衍生物的安全性检查中,JOL917和JOL918组的肝脏,脾脏,肾脏,小肠和盲肠扁桃体的总病变评分中等,而JOL919组则明显低于JOL860。 JOL917和JOL918组的脾脏和盲肠细菌计数适中,与JOL860组相比,JOL919组的细菌计数显着降低。此外,只有JOL919组的粪便样本中细菌计数明显低于JOL860组。在衍生组中观察到IgG和IgA分泌水平显着升高,而JOL919和JOL860组与对照组相比显示出有效的淋巴细胞增殖反应。在保护功效检查中,JOL919免疫组在针对野生型SE挑战后,与对照组相比,抑郁,抑郁症的肝脏和脾脏总病变明显减少,SE阳性内脏器官的数量明显减少。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号